A microRNA cluster as a target of genomic amplification in malignant lymphoma MiRNAs display dynamic temporal and spatial expression patterns, where disruption of these patterns might be associated with tumorigenesis. We recently found that C13orf25 is a target gene of 13q31-q32 gain/amplification in malignant lymphomas.
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C13orf25 encodes two variant transcripts by alternative splicing, referred to as C13orf25 transcript variants 1 and 2. Of particular interest are the seven miRNA genes (miR-17, miR-18, miR-19a, miR-19b, miR-20 and miR-92) clustered within the region of C13orf25 transcript variant 2 (C13orf25 v2). The expression of these miRNAs was investigated in the present study in an effort to determine whether these are also overexpressed concomitantly with C13orf25 v2 overexpression using 12 malignant lymphoma cell lines and 21 diffuse large B-cell lymphoma (DLBCL) cases. We recently reported array CGH analysis of genomic gains and losses of 66 cases of DLBCL. 3 In all, 21 of the 66 cases were examined for real-time quantitative polymerase chain reaction (PCR) analysis in this study. Of the 21 cases, eight cases showed a genomic gain at 13q, two cases of which showed high copy number gain (amplification) at 13q31. The remaining 13 of the 21 cases showed no copy number changes at 13q.
The cell lines used in this study were Karpas 1718 (splenic lymphoma with villous lymphocytes: SLVL), six mantle lymphoma cell lines (REC-1, Jeko-1, Z138, NCEB-1, Granta 519, SP49 and JVM2), ATN-1 (adult T-cell lymphoma cell line), Jurkat (T-cell acute lymphocytic leukemia), HT-1 (T-cell lymphoblastic lymphoma cell line, HTLV-1-negative) and HUT78 (peripheral T-cell lymphoma cell line). The HeLa cell line, which does not show copy number gain at 13q31-q32, was used as a nonlymphoma control. 4 Array CGH results indicated that four of the 12 lymphoma cell lines had copy number gain at 13q/ 13q31-q32 (Karpas 1718, REC-1, Jeko-1 and Z138). High copy number gains (amplifications) of 13q31-q32 were found in K1718, REC-1 and Jeko-1, while low copy number gain of 13q was found in Z138. On the other hand, NCEB-1, G519, SP49, JVM2, Jurkat, HUT78, HT-1 and ATN-1 did not show any copy number changes at the 13q31-q32 region. Individual genomic profiles of malignant lymphoma cell lines with and without 13q/ 13q31 gain/amplification are shown in Figure 1 .
Northern blot analysis of the seven mature miRNAs showed that six mature miRNAs (miR-17-5p, miR-17-3p, miR-19a, miR19b, miR-20 and miR-92-1) in the cell lines with a 13q31 gain/ amplification displayed overexpression significantly higher than in those without. Of these six miRNAs, expression of miR-17-3p was comparatively lower than the other five miRNAs (data not shown). The expression of mature miR-18 was markedly low level and was similar in cell lines with and without 13q gain/amplification (data not shown). MiR-18 may be subjected to modification during its maturation process to induce degradation in these cell lines. Overexpression of the six miRNAs was also found in Z138, which showed low copy number gain at chromosome 13. As shown in Figure 2 , expression of C13orf25 v2 and miRNAs correlated well with the 13q31 genomic amplifications. Real-time quantitative PCR revealed that the expression levels of C13orf25 v2 in cell lines and tumor samples with a 13q/13q31 gain were significantly higher than in cases without 13q gains (Mann-Whitney U-test, cell lines: P ¼ 0.0055; tumor samples: P ¼ 0.0059) ( Figure 3 ). These results strongly suggest that miRNAs as well as C13orf25 are targets of 13q/13q31 genomic amplification in malignant lymphomas.
We have recently provided evidence that gain/amplification of 13q31-q32 is significantly associated with shortened survival of CD5-positive DLBCL, 3 but that the gain/amplification had no impact on other prognostic factors such as LDH, performance status, stage and patient's age.
Abnormal miRNA expression of hematological malignancies has recently been reported. For example, the miR-155 precursor is enriched in Burkitt's lymphoma tissues, and the location of miR-155 correlates with a specific chromosomal translocation. 5 Frequent downregulation of miR-15 and miR-16 has been detected in chronic lymphocytic leukemia. 6 These findings strongly indicate that aberrant expression of miRNAs might contribute to hematological malignancies. To the best of our knowledge, this is the first reported study to demonstrate that regulatory RNAs correlate with genomic gain/amplification in human cancer. It has been hypothesized that miRNA genes might play an important role in tumorigenesis. Aberrant overexpression of miRNAs in human tumors might be associated with tumorigenesis by suppressing the tumor suppressor genes. Identification of the downstream targets for these miRNAs can be expected to provide new insights into the mechanism of their tumorigenesis. Real-time quantitative PCR for detecting the expression level of C13orf25 v2 (microRNA cluster) in cell lines and DLBCL tumor samples with and without 13q gain/amplifications. The primers of C13orf25 v2 were sense 5 0 -tctactgcagtgaaggcact-3 0 and antisense 5 0 -tgccagaaggagcacttagg-3 0 . The PCR fragment (170 bp) includes mature miR-17-5p, miR-17-3p and miR-18 sequences and partial sequences of pre miR-17 and pre miR-18 genes. All the experiments were carried out in duplicate. The variance between the duplicate was o5%. The expression level of C13orf25 v2 mRNA in each sample was normalized on the basis of the corresponding G6PDH content and recorded as the relative expression level. Significantly higher expression of C13orf25 v2 in cell lines (P ¼ 0.0055) and DLBCL cases (P ¼ 0.0059) with a 13q gain was found compared with those without a gain.
Figure 2
Expression analysis of C13orf25 v2 and miRNAs by Northern blotting. (a) Expression of the C13orf25 gene, miR-19a, miR-20 and miR-92 in B-cell lymphoma cell lines with and without a 13q gain/amplification. MiR-17 and miR-19b also showed the same expression pattern with these miRNAs (data not shown). K1718, Jeko-1 and REC-1 (underlined) showed high copy number gain at 13q31-q32. Z138 (underlined) showed low copy number gain at 13q. G519, NCEB-1, SP49 and JVM2 did not show 13q/13q31-q32 gain/ amplification. 5S ribosomal RNA served as a loading control. The HeLa cell line was used as a nonlymphoma control. (b). Expression of miR-19a in four tumor cases with (two cases) and without (two cases) 13q gain/amplification. CP383 showed a gain at 13q14-q34 (log 2 ratio ¼ 0.55). CP375 showed a high copy number gain at 13q31-q32 (log 2 ratio ¼ 2.62). CP373 and CP382 showed no copy number changes at 13q. Abnormalities of the mixed-lineage leukemia (MLL) gene on chromosome band 11q23 can be detected in de novo acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) as well as in therapy-related AML, particularly after treatment with DNA topoisomerase II inhibitors. 1 To date, more than 50 different translocations involving the MLL gene have been described, and so far up to 37 different partner genes have been cloned. The t(4;11)(q21;q23) results in the MLL-AF4 fusion gene and is the most frequent MLL translocation in ALL, but is rare in AML. The t(11;19)(q23;p13.3) generates the MLL-ENL fusion gene and is observed with equal frequency in AML and ALL, whereas t(9;11)(p21-22;q23), resulting in the MLL-AF9 fusion gene, is the most common MLL abnormality in AML.
Efficient and easy detection of
In infant ALL, any MLL rearrangement is associated with poor prognosis, whereas in older ALL patients, the presence of MLL-AF4 and MLL-AF9 fusion genes is associated with a worse outcome compared to other MLL rearrangements. 2 For example, ALL patients with MLL-ENL fusion gene transcripts tend to have a better prognosis than patients harboring MLL-AF4. 2 In AML, MLL-AF9 has generally been associated with a more favorable outcome. Therefore, detection and identification of the different types of MLL rearrangements is of clinical importance.
Various methods are available for the detection of MLL translocations, including cytogenetic analysis and molecular techniques like Southern blot analysis, (split-signal) fluorescence in situ hybridization (FISH) and reverse-transcriptase polymerase chain reaction (RT-PCR). Southern blot and split-signal FISH analysis of the MLL gene do not provide information on the involved partner gene, which can be identified by RT-PCR analysis for the most frequently occurring MLL translocations. Multiplex RT-PCR has previously been described for the simultaneous detection of MLL-AF4, MLL-AF9 and MLL-ENL fusion gene transcripts. 3 However, such classical end-stage RT-PCR is time consuming and post-PCR handling increases the risk of PCR product contamination. These limitations can be overcome by real-time quantitative (RQ-)PCR, but so far the reported RQ-PCR approaches focused on detection of a single MLL translocation only. 4, 5 In addition, with the classical RT-PCR, only qualitative data can be obtained, but a recent study indicates that quantification by RQ-PCR of the fusion gene transcript levels at diagnosis may be of prognostic relevance. 6 Therefore, our aim was to develop a multiplex RQ-PCR strategy for the simultaneous detection of all previously described variants of MLL-AF4, MLL-AF9 and MLL-ENL fusion gene transcripts. Such multiplex assay is preferred, given the low frequency of MLL rearrangements in ALL and AML (generally less than 5-10% of patients). To this end, we evaluated the usage of hydrolysis probes using the ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, USA) and hybridization probes in the LightCycler (Roche Diagnostics, Basel, Switzerland).
Primers and hydrolysis probes were designed using PrimerExpress software (Applied Biosystems) and OLIGO 6.0 according to the manufacturer's guidelines. Hybridization probes were designed by TIB MolBiol (Berlin, Germany). Primers and probes were designed in the MLL, AF4, AF9 or ENL genes in such a way that all previously reported breakpoints could be detected (Figure 1) . 3, 7, 8 RNA of cell lines and infant ALL patients was isolated using a GeneElute Mammalian Total RNA isolation kit (Sigma, St Louis, USA) according to the manufacturer's instructions. A cDNA reaction was performed using the previously described BIOMED-1 protocol. 9 The quality and quantity of cDNA samples was evaluated using an ABL RQ-PCR as previously described.
10 All patient samples, negative and positive controls were analyzed in duplicate. Primers and probes were tested using cell lines positive for MLL-AF4 (RS4;11, MV4-11 and ALL-PO for the e10-e4, e9-e5 and e11-e5 variants, respectively) or MLL-AF9 (THP-1 and MonoMac6 for the e9-e5 and e11-e5 variants, respectively) or using an MLL-ENL-positive patient sample (ENLC3 with the e10-e2 variant).
First, fusion gene-specific multiplex RQ-PCRs containing two forward MLL primers, two MLL probes and either two AF4, three AF9 or two ENL reverse primers were developed for the TaqMan and for the LightCycler. All three multiplex RQ-PCRs efficiently detected corresponding fusion transcript variants of MLL-AF4, MLL-AF9 and MLL-ENL in control samples. Subsequently, full multiplex RQ-PCRs containing two forward MLL primers, two MLL probes and two AF4, three AF9 and two ENL reverse primers were developed for the TaqMan and for the LightCycler to simultaneously detect MLL-AF4, MLL-AF9 and
